Advanced glycated albumin impairs HDL anti-inflammatory activity and primes macrophages for inflammatory response that reduces reverse cholesterol transport

Imagem de Miniatura
Arquivos
art_OKUDA_Advanced_glycated_albumin_impairs_HDL_anti_inflammatory_activity_2012.PDF (450.57 KB)
Citações na Scopus
38
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
Citação
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, v.1821, n.12, p.1485-1492, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: We investigated the effect of advanced glycated albumin (AGE-albumin) on macrophage sensitivity to inflammation elicited by S100B calgranulin and lipopolysaccharide (LPS) and the mechanism by which HDL modulates this response. We also measured the influence of the culture medium, isolated from macrophages treated with AGE-albumin, on reverse cholesterol transport (RCT). Methods and results: Macrophages were incubated with control (C) or AGE-albumin in the presence or absence of HDL, followed by incubations with S100B or LPS. Also, culture medium obtained from cells treated with C- or AGE-albumin, following S100B or LPS stimulation was utilized to treat naive macrophages in order to evaluate cholesterol efflux and the expression of HDL receptors. In comparison with C-albumin, AGE-albumin, promoted a greater secretion of cytokines after stimulation with S100B or LPS. A greater amount of cytokines was also produced by macrophages treated with AGE-albumin even in the presence of HDL Cytokine-enriched medium, drawn from incubations with AGE-albumin and S100B or LPS impaired the cholesterol efflux mediated by apoA-I (23% and 37%, respectively), HDL2 (43% and 47%, respectively) and HDL3 (20% and 8.5%, respectively) and reduced ABCA-1 protein level (16% and 26%, respectively). Conclusions: AGE-albumin primes macrophages for an inflammatory response impairing the RCT. Moreover, AGE-albumin abrogates the anti-inflammatory role of HDL, which may aggravate the development of atherosclerosis in DM.
Palavras-chave
Advanced glycated albumin, Inflammation, Atherosclerosis, Reverse cholesterol transport
URI
https://observatorio.fm.usp.br/handle/OPI/465
Referências
  1. Adorni MP, 2007, J LIPID RES, V48, P2453, DOI 10.1194/jlr.M700274-JLR200
  2. Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002
  3. Barlovic DP, 2011, CLIN SCI, V121, P43, DOI 10.1042/CS20100501
  4. Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183
  5. BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178
  6. Castilho G, 2012, INT J BIOCHEM CELL B, V44, P1078, DOI 10.1016/j.biocel.2012.03.016
  7. Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
  8. Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1493, DOI 10.1152/ajpcell.00016.2006
  9. Cohen MP, 2003, ARCH BIOCHEM BIOPHYS, V419, P25, DOI 10.1016/j.abb.2003.08.012
  10. Di Bartolo BA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-224
  11. Edgel KA, 2010, ATHEROSCLEROSIS, V209, P387, DOI 10.1016/j.atherosclerosis.2009.10.019
  12. Fitzgerald ML, 2010, ATHEROSCLEROSIS, V211, P361, DOI 10.1016/j.atherosclerosis.2010.01.011
  13. Frisdal E, 2011, J BIOL CHEM, V286, P30926, DOI 10.1074/jbc.M111.264325
  14. Furusyo N, 2012, INT J CARDIOL
  15. Gerbod-Giannone MC, 2006, P NATL ACAD SCI USA, V103, P3112, DOI 10.1073/pnas.0510345103
  16. Hansel B, 2004, J CLIN ENDOCR METAB, V89, P4963, DOI 10.1210/jc.2004-0305
  17. Hodgkinson CP, 2008, ARTERIOSCL THROM VAS, V28, P2275, DOI 10.1161/ATVBAHA.108.175992
  18. Iborra RT, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-172
  19. Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1
  20. Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
  21. Liu DH, 2012, DIABETES-METAB RES, V28, P186, DOI 10.1002/dmrr.1297
  22. LOWRY OH, 1951, J BIOL CHEM, V193, P265
  23. Machado AP, 2006, INT J BIOCHEM CELL B, V38, P392, DOI 10.1016/j.biocel.2005.09.016
  24. Machado-Lima A, 2010, DIABETES, V59, pA240
  25. McGillicuddy FC, 2009, CIRCULATION, V119, P1135, DOI 10.1161/CIRCULATIONAHA.108.810721
  26. Nobecourt E, 2010, ARTERIOSCL THROM VAS, V30, P766, DOI 10.1161/ATVBAHA.109.201715
  27. Passarelli M, 1997, DIABETOLOGIA, V40, P1085, DOI 10.1007/s001250050791
  28. Pinto RD, 2012, LIPIDS, V47, P443, DOI 10.1007/s11745-011-3647-9
  29. Reznikov LL, 2004, CLIN NEPHROL, V61, P324
  30. Shaw JA, 2008, CIRC RES, V103, P1084, DOI 10.1161/CIRCRESAHA.108.182063
  31. Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391
  32. Terasaka N, 2007, P NATL ACAD SCI USA, V104, P15093, DOI 10.1073/pnas.0704602104
  33. TOBIAS PS, 1983, J IMMUNOL, V131, P1913
  34. Tsoporis JN, 2010, CIRC RES, V106, P93, DOI 10.1161/CIRCRESAHA.109.195834
  35. ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100
  36. Valencia JV, 2004, DIABETOLOGIA, V47, P844, DOI 10.1007/s00125-004-1392-9
  37. van Zoelen MAD, 2009, SHOCK, V31, P280, DOI 10.1097/SHK.0b013e318186262d
  38. VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345
  39. Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638
  40. Wang XQ, 2002, ARTERIOSCL THROM VAS, V22, pE5, DOI 10.1161/01.ATV.0000018287.03856.DD
  41. Yamamoto Y., 2011, J IMMUNOL, V2, P146
  42. Yehuda H, 2011, ATHEROSCLEROSIS, V218, P339, DOI 10.1016/j.atherosclerosis.2011.07.120
  43. Zhu X, 2008, J BIOL CHEM, V283, P22930, DOI 10.1074/jbc.M801408200

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10